0.38
+0.0347(+10.03%)
Currency In USD
| Previous Close | 0.35 |
| Open | 0.37 |
| Day High | 0.39 |
| Day Low | 0.34 |
| 52-Week High | 3.53 |
| 52-Week Low | 0.24 |
| Volume | 642,534 |
| Average Volume | 709,909 |
| Market Cap | 22.23M |
| PE | -0.26 |
| EPS | -1.44 |
| Moving Average 50 Days | 0.35 |
| Moving Average 200 Days | 1.21 |
| Change | 0.03 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $12.27 as of April 24, 2025 at a share price of $0.381. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $103.17 as of April 24, 2025 at a share price of $0.381.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
12 hours ago
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, tod
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
GlobeNewswire Inc.
Mar 20, 2025 12:00 PM GMT
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, tod
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
GlobeNewswire Inc.
Mar 19, 2025 12:00 PM GMT
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, tod